ArticleProceedings of the National Academy of Sciences of the United States of America2023
Therapy targeting antigen-specific T cells by a peptide-based tolerizing vaccine against autoimmune arthritis.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Nanoparticle-Based Tolerogenic Vaccines: Next-Generation Strategies for Autoimmune and Allergic Disease Therapies.Angewandte Chemie (International ed. in English) · 2026Review
- Possible Anti-Pain Vaccines: A Narrative Review of Emerging Strategies and Clinical Prospects.Vaccines · 2025Review
- Vaccine therapy for rheumatoid arthritis: A step forward.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Tolerogenic antigen-specific vaccine induces VISTA-enriched regulatory T cells and protects against arthritis in DRB1∗04:01 mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Self-Antigens Select B Cells: A New Perspective on B Cell Selection and Function.European journal of immunology · 2025Review
- A Spleen-Targeted Tolerogenic mRNA-LNPs Vaccine for the Treatment of Experimental Asthma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Targeted Therapy of Antibody-Induced Autoimmune Arthritis Using Peptide-Guided Nanoparticles.International journal of molecular sciences · 2024Article
- Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders.Signal transduction and targeted therapy · 2024Review
- Human MHC Class II and Invariant Chain Knock-in Mice Mimic Rheumatoid Arthritis with Allele Restriction in Immune Response and Arthritis Association.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Editorial: Exploring the role of T helper cells in autoimmune disease.Frontiers in immunology · 2024Article
- Overview of mechanisms and novel therapies on rheumatoid arthritis from a cellular perspective.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A longstanding goal has been to find an antigen-specific preventive therapy, i.e., a vaccine, for autoimmune diseases. It has been difficult to find safe ways to steer the targeting of natural regulatory antigen. Here, we show that the administration of exogenous mouse major histocompatibility complex class II protein bounding a unique galactosylated collagen type II (COL2) peptide (A
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.